<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="33552">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02026219</url>
  </required_header>
  <id_info>
    <org_study_id>IUH-IRB-13-2256</org_study_id>
    <nct_id>NCT02026219</nct_id>
  </id_info>
  <brief_title>Comparison of Clopidogrel and Ticagrelor on Microvascular Dysfunction in Acute Coronary Syndrome Patients</brief_title>
  <official_title>Comparison of Clopidogrel and Ticagrelor on Microvascular Dysfunction in Acute Coronary Syndrome Patients: The Index of MIcrocirculatory Resistance After PCI in ACS Patients Study (TIMER Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Inha University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Inha University Hospital</source>
  <oversight_info>
    <authority>Korea: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Ticagrelor is a non-thienophyridine, direct P2Y12 blocker that is more potent than
      clopidogrel and is associated with less interindividual variability. In the PLATO trial, it
      was found to be superior to clopidogrel with respect to cardiovascular outcomes and total
      mortality without increasing the risk of bleedings.

      More potent and reversible receptor bindings are possible explanation for the superior
      outcomes. Beside the potent effect on inhibition of antiplatelet function, ticagrelor has
      previously been demonstrated to increase adenosine levels by inhibiting adenosine re-uptake
      in tissue level and can induce adenosine triphosphate (ATP) release from human red cells,
      which both stimulate vasodilation of  in red blood cells.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2013</start_date>
  <primary_completion_date type="Anticipated">October 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Index of microcirculatory resistance (IMR) measured after successful coronary intervention</measure>
    <time_frame>IMR will be immediately assessed after successful PCI patients within 48hr from admission</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>wall motion score index on three month later TTE from index PCI</measure>
    <time_frame>TTE will be assessed in all enrolled patients 3 month later from index PCI</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Non-ST Segment Elevation Myocardial Infarction</condition>
  <condition>ST Segment Elevation Myocardial Infarction</condition>
  <arm_group>
    <arm_group_label>Clopidogrel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Ticagrelor</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clopidogrel</intervention_name>
    <arm_group_label>Clopidogrel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ticagrelor</intervention_name>
    <arm_group_label>Ticagrelor</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  Inclusion Criteria:

               -  Males and Females

               -  between the ages of 18 and 75 years

               -  STEMI patients treated with percutaneous coronary intervention

               -  Able to provide informed consent

          -  Exclusion Criteria:

               -  History of stroke or transient ischemic attack

               -  Platelet count &lt; 100 000/Î¼L

               -  Known Bleeding Diathesis

               -  Hematocrit &lt;30% or &gt;52%

               -  Severe Liver Dysfunction

               -  Renal Insufficiency (Creatinine Clearance &lt; 30ml/min)

               -  Pregnant females

               -  Cardiogenic shock or symptomatic hypotension or sitting SBP &lt; 95 mmHg
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Sang-Don Park, Doctor</last_name>
    <phone>82328902441</phone>
    <email>denki1@inha.ac.kr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Inha University Hospital</name>
      <address>
        <city>Incheon</city>
        <zip>400-711</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sang-Don Park, Doctor</last_name>
      <phone>82328902441</phone>
      <email>denki1@inha.ac.kr</email>
    </contact>
    <investigator>
      <last_name>Sang-Don Park</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 2, 2014</lastchanged_date>
  <firstreceived_date>December 24, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Acute Coronary Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Clopidogrel</mesh_term>
    <mesh_term>Ticagrelor</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
